Home › Myositis › North Carolina › Charlotte
Myositis clinical trials in Charlotte, NC
3 studies for Myositis are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- Atrium Health Rheumatology-Southpark, Charlotte
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RecruitingPhase 1/2
- Nkarta Investigational Site, Charlotte
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
About Myositis
Myositis means inflammation of the muscles. Two specific types are polymyositis and dermatomyositis. Read about myositis symptoms and management.
More about Myositis on MedlinePlus
Myositis trials in other cities
- Durham, NC10 studies
- Boston, MA6 studies
- Chicago, IL6 studies
- New York City, NY6 studies
- Houston, TX5 studies
- Miami, FL4 studies
- Cedar Rapids, IA4 studies
- Orange, CA3 studies
- Pittsburgh, PA3 studies
- Baltimore, MD3 studies
- Washington, DC3 studies
- Jacksonville, FL3 studies
Other studies in Charlotte
- Cancer (all types)27 studies
- Breast Cancer22 studies
- Multiple Myeloma21 studies
- Non-Small Cell Lung Cancer19 studies
- Acute Myeloid Leukemia16 studies
- Obesity16 studies
- Overweight15 studies
- Colorectal Cancer13 studies
- Ovarian Cancer12 studies
- Heart Failure11 studies
- Metastatic Cancer11 studies
- Head and Neck Squamous Cell Carcinoma10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.